The UK and US have announced a important bilateral deal that will guarantee no levies on UK pharmaceutical shipments being sold in the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has pledged to increase funding on drugs through the public health system. This pledge secures that import taxes on these key products will be held at nothing for a timeframe of the next three years.
This agreement follows recent statements to significantly raise duties on patented drug imports, with potential rates mentioned reaching 100%.
"This arrangement between the Britain bolsters the international landscape for cutting-edge drugs and introduces long-overdue equity to U.S.–U.K. drug exports," a release noted.
Economic Importance
Drugs represent one of the UK's biggest exports to the US, which is clearly the primary destination for large companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period prior to last September, the UK sold drugs totaling billions to the US. This figure represented nearly one-fifth of British export trade in that timeframe.
"This guarantee protects employment, increases investment and facilitates the UK to establish itself as a international leader for medical research," the Business and Trade Secretary remarked.
Specific UK Commitments
The pact entails several notable changes from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a aim to increase overall NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The sum manufacturers must return to the NHS to stay within budget will be limited at 15%. Previously, rebates were more than twenty percent.
Recent Tensions
This agreement follows a long-running row between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
The disagreement were exacerbated by claims that US patients were paying several times more for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or scrapped, while major funding commitments have been pledged toward American operations.
A senior figure acknowledged that the NHS needed to spend more on medicines, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
